ISUP共识会议:睾丸生殖细胞肿瘤分子遗传学检测的当前与未来应用
国际泌尿病理学会(ISUP)于2019年3月召开咨询会议,聚焦睾丸肿瘤(尤其生殖细胞肿瘤)的分子病理应用。会前对会员进行问卷调查以了解诊断实践和2014年ISUP免疫组化指南采纳情况。文章更新了睾丸生殖细胞肿瘤分类,并描述分子遗传学检测的当前与未来角色,提出三项推荐。
要点
- 所有病例应记录GCNIS存在及精子发生程度。
- 免疫组化在识别GCNIS、区分胚胎性癌与精原细胞瘤等场景为可选。
- 12号染色体短臂增益可鉴别非GCNIS与GCNIS相关GCT并支持生殖细胞起源。
核心结论
- 12p拷贝增益有助于区分非GCNIS与GCNIS相关GCT并确认原发和转移性肿瘤的生殖细胞起源。
- GCNIS存在和精子发生程度应在所有病例中记录。
研究设计与样本
- ISUP于2019年3月组织咨询会议,会前对会员进行问卷调查以了解睾丸GCT诊断实践和2014年免疫组化指南采纳情况。
主要发现
- 会前调查显示最常用免疫标记物组合包括OCT3/4、胎盘碱性磷酸酶、D2-40、SALL4、CD117和CD30用于GCT及GCNIS记录。
- 分子检测中12p拷贝增益可鉴别非GCNIS与GCNIS相关GCT并确立肿瘤的生殖细胞起源。
- 其他分子方法(全基因组和靶向遗传异常、P53突变、MDM2扩增、p53失活miR-371a-3p检测)目前未广泛用于TGCT,但miR-371a-3p有望作为恶性TGCT血清标志物。
关键数值与推荐
- 推荐1:所有病例应记录GCNIS存在及精子发生程度。
- 推荐2:免疫组化在识别GCNIS、区分胚胎性癌与精原细胞瘤、确认卵黄囊瘤和/或绒毛膜癌、鉴别精母细胞瘤与类似病变时为可选。
- 推荐3:检测12号染色体短臂增益可诊断性区分非GCNIS与GCNIS相关GCT,并支持原发和转移性肿瘤的生殖细胞起源。
临床怎么用
- 病理诊断中应常规记录GCNIS和精子发生程度。
- 免疫组化可根据推荐场景选择性使用。
- 12p增益检测可用于鉴别GCT类型和确认生殖细胞起源。
局限性
- 其他分子方法(如P53突变、MDM2扩增、miR-371a-3p检测)目前未广泛用于TGCT,其效用需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The International Society of Urological Pathology (ISUP) organized a Consultation Conference in March 2019 dealing with applications of molecular pathology in Urogenital Pathology, including testicular tumors (with a focus on germ cell tumors [GCTs]), preceded by a survey among its members to get insight into current practices in testicular germ cell tumor (TGCT) diagnostics and adoption of the ISUP immunohistochemical guidelines published in 2014. On the basis of the premeeting survey, the most commonly used immunomarker panel includes OCT3/4, placental alkaline phosphate, D2-40, SALL4, CD117, and CD30 for GCTs and the documentation of germ cell neoplasia in situ (GCNIS). Molecular testing, specifically 12p copy gain, is informative to distinguish non-GCNIS versus GCNIS related GCTs, and establishing germ cell origin of tumors both in the context of primary and metastatic lesions. Other molecular methodologies currently available but not widely utilized for TGCTs include genome-wide and targeted approaches for specific genetic anomalies, P53 mutations, genomic MDM2 amplification, and detection of the p53 inactivating miR-371a-3p. The latter also holds promise as a serum marker for malignant TGCTs. This manuscript provides an update on the classification of TGCTs, and describes the current and future role of molecular-genetic testing. The following recommendations are made: (1) Presence of GCNIS should be documented in all cases along with extent of spermatogenesis; (2) Immunohistochemical staining is optional in the following scenarios: identification of GCNIS, distinguishing embryonal carcinoma from seminoma, confirming presence of yolk sac tumor and/or choriocarcinoma, and differentiating spermatocytic tumor from potential mimics; (3) Detection of gain of the short arm of chromosome 12 is diagnostic to differentiate between non-GCNIS versus GCNIS related GCTs and supportive to the germ cell origin of both primary and metastatic tumors.
引用
- Looijenga LHJ, Van der Kwast TH, Grignon D, et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. Am J Surg Pathol. 2020. PMID: 32205480. doi:10.1097/PAS.0000000000001465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。